Retinal Disease Therapeutics Market Size, Share and Industry Analysis By Disease Indication (Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema, Retinal Vein Occlusion), Distribution Channel (Hospital Pharmacy, Retail Pharmacy) and Regional Forecast, 2019 - 2026

Table of Content:

1. Introduction

1.1. Research Scope

1.2. Market Segmentation

1.3. Research Methodology

1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities

4. Key Insights

4.1 Recent industry developments such as mergers & acquisitions

4.2 Regulatory scenario for key countries

4.3 Prevalence of Key Retinal Diseases, in Major Countries

4.4 Pipeline Analysis

4.5 Patent Snapshot

5. Global Retinal Disease Therapeutics Market Analysis, Insights and Forecast, 2015-2026

5.1. Key Findings / Summary

5.2 Market Analysis, Insights and Forecast – By Disease Indication

5.2.1 Macular Degeneration

5.2.2 Diabetic Macular Edema

5.2.3 Diabetic Retinopathy

5.2.4 Retinal Vein Occlusion

5.2.5 Others

5.3. Market Analysis, Insights and Forecast – By End User

5.3.1 Hospital Pharmacy

5.3.2 Retail Pharmacy

5.3.3 Others

5.4. Market Analysis, Insights and Forecast – By Region

5.4.1 North America

5.4.2 Europe

5.4.3 Asia Pacific

5.4.4 Latin America

5.4.5 Middle East & Africa

6. North America Retinal Disease Therapeutics Market Analysis, Insights and Forecast, 2015-2026

6.1. Key Findings / Summary

6.2. Market Analysis – By Disease Indication

6.2.1 Macular Degeneration

6.2.2 Diabetic Macular Edema

6.2.3 Diabetic Retinopathy

6.2.4 Retinal Vein Occlusion

6.2.5 Others

6.3. Market Analysis – By End User

6.3.1 Hospital Pharmacy

6.3.2 Retail Pharmacy

6.3.3 Others

6.4. Market Analysis – By Country

6.4.1 U.S.

6.4.2 Canada

7. Europe Retinal Disease Therapeutics Market Analysis, Insights and Forecast, 2015-2026

7.1. Key Findings / Summary

7.2. Market Analysis – By Disease Indication

7.2.1 Macular Degeneration

7.2.2 Diabetic Macular Edema

7.2.3 Diabetic Retinopathy

7.2.4 Retinal Vein Occlusion

7.2.5 Others

7.3. Market Analysis – By End User

7.3.1 Hospital Pharmacy

7.3.2 Retail Pharmacy

7.3.3 Others

7.4. Market Analysis – By Country

7.4.1 Germany

7.4.2 U.K.

7.4.3 France

7.4.4 Italy

7.4.5 Spain

7.4.6 Scandinavia

7.4.7 Rest of Europe

8. Asia Pacific Retinal Disease Therapeutics Market Analysis, Insights and Forecast, 2015-2026

8.1. Key Findings / Summary

8.2. Market Analysis – By Disease Indication

8.2.1 Macular Degeneration

8.2.2 Diabetic Macular Edema

8.2.3 Diabetic Retinopathy

8.2.4 Retinal Vein Occlusion

8.2.5 Others

8.3. Market Analysis – By End User

8.3.1 Hospital Pharmacy

8.3.2 Retail Pharmacy

8.3.3 Others

8.4. Market Analysis – By Country

8.4.1 India

8.4.2 China

8.4.3 Japan

8.4.4 Australia

8.4.5 Southeast Asia

8.4.6 Rest of Asia Pacific

9. Latin America Retinal Disease Therapeutics Market Analysis, Insights and Forecast, 2015-2026

9.1. Key Findings / Summary

9.2. Market Analysis – By Type

9.2.1 Macular Degeneration

9.2.2 Diabetic Macular Edema

9.2.3 Diabetic Retinopathy

9.2.4 Retinal Vein Occlusion

9.2.5 Others

9.3. Market Analysis – By End User

9.3.1 Hospital Pharmacy

9.3.2 Retail Pharmacy

9.3.3 Others

9.4. Market Analysis – By Country

9.4.1 Brazil

9.4.2 Mexico

9.4.3 Rest of Latin America

10. Middle East &Africa Retinal Disease Therapeutics Market Analysis, Insights and Forecast,2015-2026

10.1. Key Findings / Summary

10.2. Market Analysis – By Disease Indication

10.2.1 Macular Degeneration

10.2.2 Diabetic Macular Edema

10.2.3 Diabetic Retinopathy

10.2.4 Retinal Vein Occlusion

10.2.5 Others

10.3. Market Analysis – By End User

10.3.1 Hospital Pharmacy

10.3.2 Retail Pharmacy

10.3.3 Others

10.4. Market Analysis – By Country

10.4.1 GCC

10.4.2 South Africa

10.4.3 Rest of Middle East & Africa

11. Competitive Analysis

11.1. Key Industry Developments

11.2. Global Market Share Analysis (2018)

11.3. Competition Dashboard

11.4. Comparative Analysis –Major Players

11.5. Company Profiles (Overview,Products & services, SWOT analysis, Recent developments, strategies,financials (based on availability))

11.5.1 Merck& Co., Inc.

11.5.2 Novartis AG

11.5.3 Allergan plc

11.5.4 Regeneron Pharmaceuticals, Inc.

11.5.5 Santen Pharmaceutical Co., Ltd.

11.5.6 F.Hoffmann-La Roche AG

 

12. Strategic Recommendations